In recent years, positron emission tomography (PET) with radiopharmaceuticals that target prostate-specific membrane antigen (PSMA) has become the mainstay for imaging patients with prostate cancer owing to its improved sensitivity and diagnostic performance compared with conventional imaging methods such as computed tomography (CT), magnetic resonance imaging (MRI), and bone scintigraphy [2,4]. This evidence concerns the gene FOLH1 and Familial prostate cancer.